We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
-4.68%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
-$162M
(-13%)
Cap. Flow
-$69.4M
Cap. Flow
% of AUM
-6.4%
Top 10 Holdings %
Top 10 Hldgs %
77.96%
Holding
37
New
2
Increased
1
Reduced
8
Closed
3
Avg Time Held
6.1
quarters
Top 10 Avg Time Held
7
quarters
Top 20 Avg Time Held
6.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$21.4M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$17.6M |
| 3 |
Autolus Therapeutics
AUTL
|
+$14.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcutis Biotherapeutics
ARQT
|
+$59.4M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
+$15.6M |
| 3 |
Adverum Biotechnologies
ADVM
|
+$14.2M |
| 4 |
Krystal Biotech
KRYS
|
+$7.48M |
| 5 |
Aclaris Therapeutics
ACRS
|
+$7.39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.61% |
| 2 | Miscellaneous | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Arcutis Biotherapeutics
ARQT
$3.28B
| $230M | 21.23% |
8,434,232
-2,108,558
| -20% | -$59.4M |
2020 Q1
5 quarters
|
|
2
Phathom Pharmaceuticals
PHAT
$566M
| $197M | 18.19% |
5,827,415
| – | – |
2019 Q4
6 quarters
|
|
3
Passage Bio
PASG
$11.7M
| $66.3M | 6.12% |
250,461
| – | – |
2020 Q1
5 quarters
|
|
4
Mirum Pharmaceuticals
MIRM
$5.17B
| $61.7M | 5.69% |
3,566,912
| – | – |
2019 Q3
7 quarters
|
|
5
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $57.4M | 5.29% |
2,082,789
-100,000
| -5% | -$1.97M |
2019 Q2
8 quarters
|
|
|
6
Iovance Biotherapeutics
IOVA
$6.57B
| $55.6M | 5.13% |
2,137,999
+825,000
| +63% | +$21.4M |
2016 Q2
20 quarters
|
|
|
7
Krystal Biotech
KRYS
$9.51B
| $53.6M | 4.94% |
787,876
-107,124
| -12% | -$7.48M |
2018 Q3
11 quarters
|
|
8
Vaxcyte
PCVX
$10.4B
| $52M | 4.79% |
2,309,554
| – | – |
2020 Q2
4 quarters
|
|
|
9
Tarsus Pharmaceuticals
TARS
$3.31B
| $41.1M | 3.79% |
1,417,157
-500,000
| -26% | -$15.6M |
2020 Q4
2 quarters
|
|
|
TRIL
10
DELISTED
Trillium Therapeutics Inc.
TRIL
| $30.3M | 2.79% |
3,123,107
| – | – |
2020 Q1
5 quarters
|
|
11
AnaptysBio
ANAB
$1.36B
| $23.3M | 2.15% |
899,700
| – | – |
2017 Q1
17 quarters
|
|
12
DELISTED
Alpine Immune Sciences Inc
ALPN
| $23.1M | 2.13% |
2,571,450
| – | – |
2017 Q3
15 quarters
|
|
13
Syndax Pharmaceuticals
SNDX
$1.25B
| $20.4M | 1.88% |
1,188,135
-246,910
| -17% | -$4.52M |
2020 Q1
5 quarters
|
|
14
Sutro Biopharma
STRO
$183M
| $18.6M | 1.72% |
100,142
| – | – |
2020 Q4
2 quarters
|
|
|
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $16.1M | 1.48% |
2,544,500
| – | – |
2020 Q2
4 quarters
|
|
|
KDNY
16
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $15.5M | 1.43% |
+1,100,000
| New | +$17.6M |
2021 Q2
0 quarters
|
|
|
17
Autolus Therapeutics
AUTL
$431M
| $15.2M | 1.4% |
+2,283,966
| New | +$14.2M |
2021 Q2
0 quarters
|
|
|
FLACU
18
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
| $15.1M | 1.39% |
1,501,000
| – | – |
2020 Q4
2 quarters
|
|
19
Regenxbio
RGNX
$479M
| $13.7M | 1.26% |
351,954
| – | – |
2020 Q3
3 quarters
|
|
20
DELISTED
Molecular Templates, Inc.
MTEM
| $10.7M | 0.99% |
91,603
| – | – |
2020 Q4
2 quarters
|
|
21
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $9.41M | 0.87% |
1,030,878
| – | – |
2018 Q3
11 quarters
|
|
22
DELISTED
ESSA Pharma
EPIX
| $9.05M | 0.83% |
316,616
| – | – |
2021 Q1
1 quarter
|
|
|
23
Aclaris Therapeutics
ACRS
$511M
| $6.51M | 0.6% |
370,733
-325,267
| -47% | -$7.39M |
2021 Q1
1 quarter
|
|
|
EPZM
24
DELISTED
Epizyme, Inc
EPZM
| $6.14M | 0.57% |
739,369
| – | – |
2020 Q4
2 quarters
|
|
|
APTX
25
DELISTED
Aptinyx Inc. Common Stock
APTX
| $5.33M | 0.49% |
1,883,244
-1,306,835
| -41% | -$3.65M |
2018 Q2
12 quarters
|
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q2 2021 Portfolio in Review
As of Q2 2021, Frazier Management held 37 positions worth $1.08B, down 13% from $1.25B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Frazier Management withdrew a net $69.4M in Q2 2021, closing 3 positions and reducing 8 holdings. Its most notable exit was Adverum Biotechnologies, an estimated $14.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, Frazier Management opened a new position in Chinook Therapeutics, Inc. Common Stock worth $15.5M.
- Frazier Management's largest Q2 2021 buy was Chinook Therapeutics, Inc. Common Stock: 1,100,000 shares worth $15.5M.
- Frazier Management added most to Iovance Biotherapeutics in Q2 2021, an estimated $21.4M increase.
- Frazier Management's biggest Q2 2021 reduction was Arcutis Biotherapeutics, cutting an estimated $59.4M.
- Frazier Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $14.2M.
- Frazier Management's ten largest holdings make up 78% of its $1.08B portfolio in Q2 2021.
- Frazier Management opened 2 new positions and closed 3 in Q2 2021.
- Frazier Management's portfolio value fell 13% quarter-over-quarter to $1.08B.
Based on Frazier Management's 13F filing for Q2 2021, filed 11 Aug 2021.